---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-22-000072"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2022-12-13T23:59:59+00:00"
generated_at: "2026-06-21T05:16:37.998657+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pacira reports Nov 2022 preliminary net product sales of $57.5M; EXPAREL unit volumes up 4% YoY

## Summary
- EXPAREL net sales $46.0M (99% of Nov 2021); unit volumes 104% of Nov 2021; selling days flat at 20.
- ZILRETTA net sales $10.0M; iovera° net sales $1.5M (unchanged YoY).
- Expanded contracting and 340B pricing expected to drive volume growth and be accretive in 2023.
- No 2022 revenue or gross margin guidance provided due to COVID-19 and labor shortage uncertainty.
- Company continues monthly intra-quarter sales reporting until visibility improves.

## SEC filing metadata
- accession: 0001396814-22-000072
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2022-12-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/0001396814-22-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/pcrx-20221213.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-22-000072
- JSON: https://secwatch.observer/filing/0001396814-22-000072.json
- Plain text: https://secwatch.observer/filing/0001396814-22-000072.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported the month of November 2022 results: revenue $57.5 million.
  - Period: the month of November 2022
  - Revenue: $57.5 million
  - Result: preliminary results
  source text: Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $57.5 million for the month of November 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681422000072/0001396814-22-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.